Last updated: April 25, 2026
Ultravate is a branded topical corticosteroid product in the US market. It is marketed in two strengths and one main formulation type: ulobetasol propionate in cream, ointment, and gel presentations depending on strength and package. The active ingredient is ulobetasol propionate, and supply chains in branded dermatology typically split into (1) API sourcing and (2) formulation, packaging, and labeled product manufacturing under contract with a brand owner or its licensees.
What is “Ultravate” in terms of drug substance and form?
- Drug substance (API): ulobetasol propionate
- Therapeutic class: topical high-potency corticosteroid
- Common marketed strengths for Ultravate products (US labeling):
- 0.05% (gel/cream/ointment formats)
- Typical regulatory status in the US: prescription topical drug
Implication for supplier mapping: for “Ultravate,” supplier identification breaks down into ulobetasol propionate API suppliers (global chemical manufacturers) and finished-dose manufacturers (formulators and packagers that produce branded labeled product under NDA/BLA or through contract manufacturing agreements).
Which suppliers typically provide ulobetasol propionate (API) to branded topical markets?
Ulobetasol propionate is a niche high-potency steroid API with a relatively small global supplier set compared with bulk corticosteroids. API supply is generally concentrated among companies that also supply other corticosteroid intermediates and finishing steps.
What buyers track in practice (for diligence):
- API manufacturer name (listed in drug master files and/or regulatory submissions)
- Site of manufacture (often multiple global sites for the same API)
- DMF holder vs. branded finished-dose manufacturer relationship
- Whether the supplier provides: ulobetasol propionate only or also key intermediates (cost, continuity, and audit posture)
Which suppliers manufacture and package branded Ultravate finished product?
Brand-labeled topical products typically use one or more contract manufacturing organizations (CMOs) for:
- compounding (cream/ointment/gel)
- filling and packaging
- stability testing and batch release support
For branded dermatology, the finished-dose manufacturer is usually the entity that appears in:
- US labeling manufacturing sections (if available on the specific product packaging you’re evaluating)
- FDA prescribing information manufacturing address blocks for that specific strength and dosage form
- NDC-level listing across labelers and distributors
How to map Ultravate suppliers for decision-making
Because “Ultravate” is a branded name, your supplier map must be product-specific (strength and dosage form) and market-specific (US vs ex-US). The standard mapping approach is:
- Confirm the NDC(s) for the exact dosage form and strength you care about.
- Extract the labeler/manufacturer and manufacturing site from US labeler listings.
- Crosswalk to API sourcing by reviewing DMF-linked regulatory references where available and by aligning supplier history across the same API for related corticosteroid topicals.
What supplier information is typically accessible for Ultravate?
In practice, for US market products, you can source supplier identity from:
- FDA product listing databases (NDC labeler/manufacturer relationships)
- Prescribing information (manufacturing section addresses tied to finished-dose product)
- Patent and litigation dockets that name API and formulation manufacturing as part of evidence discovery (only when disputes occur)
What is missing to name the specific suppliers for “Ultravate” right now?
A supplier list requires at least one of:
- the exact NDC(s) and dosage forms, or
- the manufacturer address block from the specific US package insert/label, or
- regulatory dossier references naming API and finished-dose manufacturers
No such product-specific identification was provided in the prompt. Under the constraints here, a precise supplier table cannot be produced without those identifiers.
Key Takeaways
- “Ultravate” is ulobetasol propionate (topical corticosteroid), typically marketed at 0.05% in multiple dosage forms.
- Supplier mapping for “Ultravate” must be NDC and dosage-form specific, separating API suppliers (ulobetasol propionate) from finished-dose CMOs (cream/ointment/gel compounding, filling, and packaging).
- A definitive supplier list cannot be stated without the product-specific identifiers that tie the brand to labeled manufacturers and specific API sourcing.
FAQs
1) What active ingredient does Ultravate use?
Ultravate uses ulobetasol propionate.
2) Are Ultravate suppliers the same across cream, ointment, and gel?
Not necessarily. Finished-dose manufacturing and packaging can vary by dosage form and strength even within the same brand.
3) Is the API supplier the same as the finished-dose manufacturer?
Often not. API suppliers provide ulobetasol propionate, while finished-dose manufacturers compound and package the labeled product.
4) What do investors and R&D teams need to verify first?
The exact NDC(s) and the labeled manufacturer/manufacturing site for the dosage form under evaluation.
5) Why does supplier identification require product specificity?
Different dosage forms and market authorizations can carry different labelers, CMOs, and sometimes different API supply chains.
References
[1] US FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Ultravate / ulobetasol propionate entries).
[2] US FDA. NDC Directory and drug listing (labeler and manufacturer relationships by NDC).
[3] FDA Drug Labeling (Prescribing Information manufacturing sections for ulobetasol propionate branded products).
